Commercial eggshell membrane supplements show poor solubility, digestion resistance, and no anti-inflammatory activity in human immune cells
Background
Patients with osteoarthritis (OA) frequently use dietary supplements for joint health, with eggshell membrane (ESM) proteins widely marketed as natural bioactive compounds. Despite their popularity, the physiological plausibility of orally administered ESM supplements as anti-inflammatory agents remains underexplored. Current standard-of-care often involves NSAIDs or other symptomatic treatments, which may have side effects or limited efficacy, highlighting a need for effective, well-substantiated alternatives. This study investigates whether commercial ESM products can even be absorbed and exert immunomodulatory effects.
Study Design
Researchers evaluated three commercial ESM formulations (NEM®, Torolis®, and Biova®) for solubility, digestibility, and immunomodulatory potential. Protein solubility was assessed in physiological saline and under simulated gastric (pH 2) and intestinal (pH 5.8) conditions, including treatment with dithiothreitol (DTT) to address disulfide bonds. Digestibility was examined via SDS-PAGE after exposure to pepsin, pancrelipase (Creon®), or sequential digestion. Released peptides were identified using MALDI-TOF mass spectrometry. Immunomodulatory effects of Biova® were tested on human peripheral blood mononuclear cells (PBMC) by measuring cytokine release (IL-6, TNFα, IL-17A, granzyme B) after stimulation with lipopolysaccharide (LPS) or Phorbol 12-myristate 13-acetate/Ionomycin.
Results
Two of the three commercial ESM products, NEM® and Torolis®, exhibited extremely low solubility, registering less than 0.3% under all tested physiological conditions, even after treatment with DTT to break disulfide bonds. While Biova® demonstrated high solubility, approximately 90%, simulated gastrointestinal digestion yielded minimal peptide generation. Only non-physiological extraction methods produced sporadic trace peptides, most of which lacked known anti-inflammatory relevance. In human PBMC assays, Biova® paradoxically increased IL-6 levels following LPS stimulation.
A non-significant reduction in
TNFαwas observed with Biova®, and no discernible effect was found onIL-17Aorgranzyme Brelease. These findings collectively suggest that commercial ESM supplements are largely insoluble, resistant to enzymatic digestion, and do not exhibit meaningful anti-inflammatory activity in human immune cells under the conditions tested.
Key Findings
- NEM® and Torolis® ESM supplements showed extremely low solubility (<0.3%) under all physiological conditions.
- Biova® ESM was highly soluble (~90%) but yielded minimal peptide generation after simulated GI digestion.
- Biova® increased IL-6 levels in human PBMCs after LPS stimulation, indicating a pro-inflammatory effect.
- Biova® showed a non-significant TNFα reduction and no effect on IL-17A or granzyme B in PBMC assays.
- Overall, commercial ESM supplements were largely insoluble, digestion-resistant, and lacked meaningful anti-inflammatory activity.
Why It Matters
These findings significantly challenge the plausibility of orally administered eggshell membrane supplements as effective anti-inflammatory agents for joint health. For peptide users and biohackers, this suggests that current commercial ESM products may not deliver the advertised benefits due to poor bioavailability and lack of direct immunomodulatory action. The study indicates that simply consuming these supplements might not translate into therapeutic effects, as the active components are unlikely to be absorbed or reach target tissues in a functional form. This research underscores the importance of rigorous scientific validation for dietary supplements and suggests that a usable protocol for ESM in OA is far from established, requiring fundamental improvements in formulation or delivery to overcome solubility and digestion barriers.
eggshell membrane
osteoarthritis
inflammation
solubility
digestibility
in-vitro